<DOC>
	<DOC>NCT02813655</DOC>
	<brief_summary>The aim of the study is to assess the efficacy and safety of Synacthène® versus placebo in the treatment of post-dural puncture syndrome in patients receiving epidural analgesia, spinal analgesia, or combined spinal-epidural analgesia for labour.</brief_summary>
	<brief_title>Evaluation of the Effectiveness and Tolerance of Tetracosactide Synacthen® in the Treatment of Post Dural Puncture Headaches (ESYBRECHE)</brief_title>
	<detailed_description />
	<mesh_term>Headache</mesh_term>
	<mesh_term>Wounds and Injuries</mesh_term>
	<mesh_term>Post-Dural Puncture Headache</mesh_term>
	<mesh_term>Cosyntropin</mesh_term>
	<criteria>All women who received epidural, spinal, or combined spinalepidural labour analgesia and presenting postdural puncture headache: Intense: with ≥3 / 10 numerical rating pain scale Appearing within 5 days after delivery Aggravating in sitting or standing position and / or improving supine Can be associated with one of the following criteria: tinnitus, nausea, photophobia, neck stiffness or pain, hearing loss After exclusion of clinically differential diagnoses (preeclampsia or eclampsia, cerebral venous thrombosis, migraine) Age greater than or equal to 18 years Affiliation to social security scheme Inform Consent signed after oral and written information Presence of diplopia (indication of immediate blood patch) Contraindication to ACTH or Synacthène® (unbalanced hypertension, uncontrolled diabetes, uncontrolled psychosis, infectious viral disease state or evolving) Processing of Torsade de Pointe provider (astenizole, bepridil, erythromycin IV, halofantrine, pentamidine, sparfloxacin, sultopride, terfenadine, vincamine) Live vaccine in the months prior to inclusion Hypersensitivity to Synacthène® Patient who have previously received Synacthène® after delivery Contraindication to blood patch (fever or leukocytosis, HIV or HCV patient) Eclampsia or preeclampsia during this pregnancy Patient who have received prophylactic blood patch (at diagnosis of Accidental Dural Puncture) Minor under 18 or protected Psychological disorders do not allowing informed consent Refusal of participation in the study or participation in another ongoing interventional study Withdrawal of consent</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>tetracosactide</keyword>
	<keyword>Synacthène®</keyword>
	<keyword>cosyntropin</keyword>
	<keyword>post-dural syndrom</keyword>
	<keyword>post-dural puncture headache</keyword>
</DOC>